Evidence map›Paper›PMID 36119787›Full record

ArticleGlobal health & medicine2022

No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.

Masaaki Korenaga, Kazumoto Murata, Namiki Izumi, Nobuharu Tamaki, Osamu Yokosuka, Tetsuo Takehara, Naoya Sakamoto, Goki Suda, Shuhei Nishiguchi, Hirayuki Enomoto and 21 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01975675 (A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01975675 phase3completednot on this map

A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection

TypeinterventionalSponsorGilead SciencesRan2013 to 2014Enrolled341ConditionsChronic HCV InfectionArmsLDV/SOF, RBV
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 15 institutions in 1 country.

Masaaki KorenagaThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Kazumoto MurataGenome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Japan Red Cross Musashino Hospital, Tokyo, Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology, Japan Red Cross Musashino Hospital, Tokyo, Japan.
Osamu YokosukaFunabashi Central Hospital, Funabashi, Japan.
Tetsuo TakeharaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Goki SudaDepartment of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shuhei NishiguchiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Hirayuki EnomotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Fusao IkedaDepartment of Gastroenterology, Okayama University Hospital, Okayama, Japan.
Mikio YanaseDepartment of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan.
Hidenori ToyodaDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
Takuya GendaDepartment of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Takeji UmemuraDepartment of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
Hiroshi YatsuhashiClinical Research Center, National Hospital Organization, Nagasaki Medical Center, Nagasaki, Japan.
Kazumi YamasakiClinical Research Center, National Hospital Organization, Nagasaki Medical Center, Nagasaki, Japan.
Tatsuya IdeDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Nobuo TodaDepartment of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan.
Tatsuo KandaDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Kazushige NireiDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Hiroaki HagaDepartment of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Yoichi NishigakiDepartment of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan.
Kunio NakaneDepartment of Gastroenterology, Akita City Hospital, Akita, Japan.
Masao OmataGenome Analysis Center, Yamanashi Prefecture Central Hospital, Yamanashi, Japan.
Hitoshi MochizukiThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Yoshihiko AokiThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Masatoshi ImamuraThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Tatsuya KantoThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Masashi MizokamiGenome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan.
National Center for Global Health and Medicine · JPHyogo Medical University · JPNagasaki Medical Center · JPNihon University · JPYamagata University · JPAkita University Hospital · JPFunabashi Central Hospital · JPGifu Municipal Hospital · JPJuntendo University Shizuoka Hospital · JPKurume University · JPMitsui Memorial Hospital · JPOgaki Municipal Hospital · JPOkayama University Hospital · JPOsaka University · JPShinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well-known that sustained virological response (SVR) by interferon (IFN)-based therapy against hepatitis C virus (HCV) infection reduced the incidence of hepatocellular carcinoma (HCC). However, whether IFN-free direct-acting antivirals reduce the risk of HCC is controversial. Therefore, this study aims to compare the incidence of HCC after the achievement of SVR between sofosbuvir combined with ledipasvir (SOF/LDV) and simeprevir with pegylated interferon plus ribavirin (Sim+IFN). Japanese patients with HCV infection (genotype 1) who achieved SVR between January 2013 and December 2014 by SOF/LDV (NCT01975675,

Indexed as

direct-acting antiviralshepatitis C virusinterferon

Identifiers

PMID36119787
PMCPMC9420328
OpenAlexW4292824569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.